BNP Paribas Asset Management
DAWN

BNP Paribas Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

BNP Paribas Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.3K Buy
1,088
+324
+42% +$4.57K ﹤0.01% 1984
2025
Q4 		$7K Buy
+764
New +$6.38K ﹤0.01% 2242
2025
Q3 		– Sell
-750
Closed -$5K – 1920
2025
Q2 		$5K Buy
+750
New +$5.16K ﹤0.01% 1994

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

BNP Paribas Asset Management's DAWN Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Day One Biopharmaceuticals (DAWN) stake by 42% in Q1 2026, buying an estimated $4.57K and bringing the position to 1,088 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

BNP Paribas Asset Management first reported a position in DAWN in Q2 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • BNP Paribas Asset Management held 1,088 shares of Day One Biopharmaceuticals worth $23.3K as of Q1 2026.
  • BNP Paribas Asset Management bought 324 Day One Biopharmaceuticals shares in Q1 2026, an estimated $4.57K.
  • Day One Biopharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1984 holding.
  • BNP Paribas Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.